We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
Read MoreHide Full Article
Fennec Pharmaceuticals Inc., (FENC - Free Report) announced that it received a Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for Pedmark (a unique formulation of sodium thiosulfate).
The NDA was seeking approval for the candidate for intravenous administration to prevent ototoxicity associated with cisplatin chemotherapy in pediatric patients in the age group of a month to 18 years with localized, non-metastatic, solid tumors.
Per management, platinum-based therapies cause ototoxicity or hearing loss, which is permanent, irreversible and particularly harmful to the pediatric cancer survivors.
The CRL was issued on Nov 29 post the target action date of Nov 27.
The letter was issued due to the identification of manufacturing deficiencies. Fennec plans to request a Type A meeting with the FDA authorities to discuss these deficiencies and other matters described in the CRL as well as the steps required for the resubmission of the NDA.
Pedmark was granted a Breakthrough Therapy and a Fast Track Designation by the FDA in March 2018. It also enjoys an Orphan Drug status.
The marketing authorization application (MAA) for sodium thiosulfate is currently under evaluation by the European Medicines Agency (EMA). It will be marketed in the EU as Pedmarqsi.
Shares are trading down in the pre-market session on the abovementioned news as investors are clearly disappointed with the delay in the approval yet again. In fact, the stock has plunged 35.8% in the year compared with the industry’s decline of 18.9%.
Image Source: Zacks Investment Research
We remind investors that the NDA was resubmitted to the FDA earlier in the year. Fennec had received a CRL in August 2010 as well due to deficiencies identified with the facility of the drug product manufacturer.
Loss per share estimates for Sarepta have narrowed from $6.95 to $4.99 for 2021 and from $4.83 to $3.61 for 2022 in the past 30 days. SRPT delivered an earnings surprise of 11.06%, on average, in the last four quarters.
Loss per share estimates for Viking Therapeutics have narrowed to $3.16 from $3.55 for 2021 and to $3.47 from $3.63 for 2022 in the past 30 days. VKTX delivered an earnings surprise of 2.06%, on average, in the last four quarters.
Editas Medicine’s loss per share estimates have narrowed to 74 cents from 81 cents for 2021 and to $1.08 from $1.18 for 2022 in the past 30 days. EDIT’s earnings surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
Fennec Pharmaceuticals Inc., (FENC - Free Report) announced that it received a Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for Pedmark (a unique formulation of sodium thiosulfate).
The NDA was seeking approval for the candidate for intravenous administration to prevent ototoxicity associated with cisplatin chemotherapy in pediatric patients in the age group of a month to 18 years with localized, non-metastatic, solid tumors.
Per management, platinum-based therapies cause ototoxicity or hearing loss, which is permanent, irreversible and particularly harmful to the pediatric cancer survivors.
The CRL was issued on Nov 29 post the target action date of Nov 27.
The letter was issued due to the identification of manufacturing deficiencies. Fennec plans to request a Type A meeting with the FDA authorities to discuss these deficiencies and other matters described in the CRL as well as the steps required for the resubmission of the NDA.
Pedmark was granted a Breakthrough Therapy and a Fast Track Designation by the FDA in March 2018. It also enjoys an Orphan Drug status.
The marketing authorization application (MAA) for sodium thiosulfate is currently under evaluation by the European Medicines Agency (EMA). It will be marketed in the EU as Pedmarqsi.
Shares are trading down in the pre-market session on the abovementioned news as investors are clearly disappointed with the delay in the approval yet again. In fact, the stock has plunged 35.8% in the year compared with the industry’s decline of 18.9%.
We remind investors that the NDA was resubmitted to the FDA earlier in the year. Fennec had received a CRL in August 2010 as well due to deficiencies identified with the facility of the drug product manufacturer.
Fennec currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Sarepta Therapeutics, Inc. (SRPT - Free Report) , Viking Therapeutics (VKTX - Free Report) and Editas Medicine, Inc. (EDIT - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Sarepta have narrowed from $6.95 to $4.99 for 2021 and from $4.83 to $3.61 for 2022 in the past 30 days. SRPT delivered an earnings surprise of 11.06%, on average, in the last four quarters.
Loss per share estimates for Viking Therapeutics have narrowed to $3.16 from $3.55 for 2021 and to $3.47 from $3.63 for 2022 in the past 30 days. VKTX delivered an earnings surprise of 2.06%, on average, in the last four quarters.
Editas Medicine’s loss per share estimates have narrowed to 74 cents from 81 cents for 2021 and to $1.08 from $1.18 for 2022 in the past 30 days. EDIT’s earnings surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.